여성 건강 진단 시장 : 질환별, 검사 유형별, 기술별, 검체 유형별, 최종 사용자별, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Women's Health Diagnostics Market is projected to grow by USD 94.71 billion at a CAGR of 15.79% by 2032.

Women's health diagnostics is moving from episodic testing to continuous, precision-oriented care across breast cancer screening, cervical cancer screening, prenatal testing, fertility assessment, sexually transmitted infection testing, osteoporosis evaluation, and hormonal health monitoring. Demand is supported by measurable disease burden: WHO reports breast cancer caused about 2.3 million new cases and 670,000 deaths in 2022, while cervical cancer accounted for more than 660,000 new cases and about 350,000 deaths in the same year.

The landscape is also shaped by underdiagnosed and often delayed-diagnosis conditions such as endometriosis, which WHO estimates affects roughly 10% of reproductive-age women and girls, and polycystic ovary syndrome, estimated at 8% to 13% of reproductive-age women. These data points reinforce the need for accessible women's health diagnostics, molecular testing, imaging, point-of-care diagnostics, and digital platforms that enable earlier detection, better risk stratification, and improved follow-up.

Transformative Shifts in Women's Health Diagnostics

The women's health diagnostics landscape is transforming through decentralization, prevention-focused screening, and stronger integration between diagnostics and care pathways. HPV DNA testing is increasingly prioritized for cervical cancer prevention, while digital mammography, ultrasound, MRI, and risk-based screening models are improving detection of breast disease in dense breast tissue and high-risk populations.

At the same time, home-based sampling, self-collection, laboratory-developed tests, and point-of-care platforms are expanding access beyond hospitals and specialty clinics. Regulatory oversight is becoming more rigorous through frameworks such as the EU In Vitro Diagnostic Regulation and U.S. FDA expectations for analytical validity, clinical validity, cybersecurity, and software-enabled diagnostics. These shifts favor organizations that combine clinical evidence, affordable access, regulatory discipline, and scalable digital infrastructure.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across women's health diagnostics by supporting image interpretation, risk stratification, workflow prioritization, and personalized screening intervals. In breast imaging, AI-enabled tools are used to flag suspicious findings and support radiology workflow efficiency; in cervical screening, computer-assisted cytology and digital pathology can help standardize review quality where trained specialists are limited.

The long-term impact depends on safe deployment. AI models must be validated across age groups, ethnicities, imaging devices, laboratory systems, and care settings to reduce bias and avoid missed diagnoses. Industry vendors also need transparent model governance, post-market monitoring, explainability, cybersecurity controls, and compliance with medical device software rules. When implemented responsibly, AI can improve diagnostic productivity and consistency without replacing clinician judgment.

Key Regional Insights

Asia-Pacific is one of the most dynamic regions for women's health diagnostics because of large populations, rising cancer screening investment, and expanding molecular testing capacity in China, India, Japan, Australia, and South Korea. The region's needs span HPV testing, prenatal screening, fertility diagnostics, breast imaging, and decentralized testing models that can serve both urban specialty centers and rural populations. North America remains highly innovation-driven, supported by advanced imaging networks, genetic testing adoption, CLIA-certified laboratories, preventive screening guidelines, and payer attention to earlier diagnosis and care pathway efficiency.

Latin America shows strong need for cervical cancer and maternal health diagnostics, with Mexico and Brazil expanding public screening while still facing access gaps in rural and lower-income communities. Europe benefits from organized screening programs, strong laboratory standards, population health registries, and IVDR-driven quality expectations, supporting demand for clinically validated tests and interoperable diagnostic data systems. The Middle East, particularly Gulf health systems, is investing in digital hospitals, fertility services, oncology diagnostics, and women's specialty care, while Africa has substantial unmet need for HPV testing, pregnancy diagnostics, infectious disease testing, and affordable point-of-care platforms that can operate in resource-constrained settings.

Key Group Insights

ASEAN demand is rising as Indonesia, Vietnam, Thailand, Malaysia, and the Philippines expand maternal health services, cervical cancer prevention, and infectious disease testing, making affordable HPV testing, self-sampling, and decentralized diagnostics critical. GCC countries are prioritizing women's specialty hospitals, fertility services, oncology screening, and digital health infrastructure, creating demand for premium imaging, molecular diagnostics, connected laboratory systems, and privacy-secure patient data platforms.

The European Union is shaped by organized cancer screening, data protection rules, cross-border health quality objectives, and IVDR compliance, rewarding clinically validated tests with strong analytical evidence. BRICS countries combine large patient volumes with local manufacturing ambitions, expanding laboratory networks, and public health screening needs across cervical cancer, maternal health, and reproductive medicine. G7 markets lead in innovation adoption, reimbursement sophistication, advanced imaging, genomics, and AI-enabled diagnostics, while NATO members place added emphasis on supply chain resilience, cybersecurity, interoperable health systems, and continuity of essential diagnostic services.

Key Country Insights

The United States leads in advanced women's health diagnostics through molecular testing, breast imaging, reproductive genetics, companion diagnostics, and digital pathology, supported by extensive specialty networks and regulatory expectations for test performance. Canada emphasizes equitable screening access across provinces and remote communities, with continued attention to breast, cervical, and prenatal diagnostics. Mexico and Brazil are expanding cervical cancer prevention, maternal diagnostics, and laboratory capacity, with Brazil also serving as a major Latin American clinical and laboratory hub for oncology, infectious disease, and reproductive health testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from organized screening programs, established clinical guidelines, and strong diagnostic infrastructure across pathology, imaging, and molecular testing, while Russia maintains demand across oncology, prenatal testing, and reproductive health despite procurement and access complexity. In Asia-Pacific, China and India offer scale for HPV testing, prenatal screening, infertility diagnostics, breast imaging, and point-of-care diagnostics, supported by growing hospital networks and public health initiatives. Japan, Australia, and South Korea show high adoption of advanced imaging, laboratory automation, digital health integration, and evidence-based screening practices, positioning them as important early adopters for precision women's health diagnostics.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize clinically validated products that address high-burden conditions, including breast cancer, cervical cancer, infertility, endometriosis, PCOS, sexually transmitted infections, pregnancy complications, and osteoporosis. Product strategies should combine high-sensitivity molecular diagnostics, imaging support, self-sampling, point-of-care workflows, and digital follow-up tools that reduce missed appointments and speed referral to care.

Commercial success will depend on evidence generation, regulatory readiness, and inclusive access. Organizations should validate tests in diverse populations, build payer evidence around earlier detection and avoided downstream costs, partner with public screening programs, and design AI governance from the start. Local manufacturing, resilient supply chains, cybersecurity readiness, and training programs for clinicians and laboratory staff will strengthen adoption in both mature and emerging markets.

Research Methodology

This executive summary is developed from a structured secondary research approach using publicly available, authoritative sources, including WHO, IARC, CDC, FDA, NIH, OECD, World Bank, national screening agencies, peer-reviewed journals, and regulatory guidance. Disease burden, screening practices, diagnostic adoption, policy priorities, and technology trends were assessed to identify reliable growth drivers in women's health diagnostics.

Insights were triangulated across epidemiology, technology readiness, regulatory conditions, reimbursement signals, healthcare capacity, and regional access indicators. The analysis emphasizes verified indicators rather than unsupported market-size claims and focuses on practical implications for diagnostic manufacturers, laboratories, healthcare providers, investors, policymakers, and public health stakeholders.

Conclusion

Women's health diagnostics is entering a high-impact phase defined by earlier detection, molecular precision, digital workflow integration, AI-supported interpretation, and expanded access. The strongest opportunities are concentrated in breast cancer screening, HPV and cervical cancer testing, prenatal and fertility diagnostics, infectious disease testing, osteoporosis evaluation, and diagnostics for chronic gynecologic conditions that remain underrecognized.

Organizations that combine scientific credibility, regulatory discipline, inclusive validation, and scalable delivery models will be best positioned to improve outcomes and capture sustainable growth. As health systems focus on prevention, population health, and value-based care, women's health diagnostics will remain central to reducing avoidable mortality, improving reproductive health, and closing long-standing gaps in care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Women's Health Diagnostics Market, by Disease Indication

• 7.1. Cardiovascular Conditions
• 7.2. Infectious Diseases
  • 7.2.1. HIV
  • 7.2.2. Human Papillomavirus
• 7.3. Metabolic Disorders
  • 7.3.1. Diabetes
  • 7.3.2. Thyroid Disorders
• 7.4. Oncology
  • 7.4.1. Breast Cancer
  • 7.4.2. Cervical Cancer
  • 7.4.3. Ovarian Cancer
• 7.5. Pregnancy And Fertility
  • 7.5.1. Ovulation Test
  • 7.5.2. Pregnancy Test

8. Women's Health Diagnostics Market, by Test Type

• 8.1. Instruments
  • 8.1.1. Benchtop Instruments
  • 8.1.2. Point Of Care Instruments
• 8.2. Kits And Reagents
  • 8.2.1. Immunoassays
  • 8.2.2. Lateral Flow Assays
  • 8.2.3. Molecular Diagnostics Kits
• 8.3. Software And Services
  • 8.3.1. Informational Software
  • 8.3.2. Services

9. Women's Health Diagnostics Market, by Technology

• 9.1. Biochemical Analysis
  • 9.1.1. Colorimetry
  • 9.1.2. Fluorometry
• 9.2. Immunoassay
• 9.3. Molecular Diagnostics
  • 9.3.1. Next Generation Sequencing
  • 9.3.2. PCR

10. Women's Health Diagnostics Market, by Sample Type

• 10.1. Blood
• 10.2. Saliva
• 10.3. Tissue
• 10.4. Urine

11. Women's Health Diagnostics Market, by End User

• 11.1. Home Care Settings
• 11.2. Hospital And Diagnostic Centers
• 11.3. Research Laboratories

12. Women's Health Diagnostics Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Women's Health Diagnostics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Women's Health Diagnostics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Women's Health Diagnostics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Beckman Coulter, Inc.
• 17.3. Becton, Dickinson and Company
• 17.4. binx health, inc.
• 17.5. Bio-Rad Laboratories, Inc.
• 17.6. Biomerieux SA
• 17.7. Cardinal Health, Inc.
• 17.8. Chembio Diagnostic Systems, Inc.
• 17.9. Cook Medical, Inc.
• 17.10. Danaher Corporation
• 17.11. Daye Ltd.
• 17.12. EKF Diagnostics Holdings PLC
• 17.13. Esaote S.p.A.
• 17.14. F. Hoffmann-La Roche Ltd.
• 17.15. FUJIFILM Holdings Corporation
• 17.16. GE Healthcare
• 17.17. Guided Therapeutics, Inc.
• 17.18. Hertility Health Ltd.
• 17.19. Hill-Rom Holdings, Inc.
• 17.20. Hologic, Inc.
• 17.21. Juno Bio Ltd.
• 17.22. Koninklijke Philips N.V.
• 17.23. MedGyn Products, Inc.
• 17.24. NeuroLogica Corporation
• 17.25. Nova Biomedical
• 17.26. Quest Diagnostics Incorporated
• 17.27. Sekisui Diagnostics, LLC
• 17.28. Siemens AG
• 17.29. SuperSonic Imagine
• 17.30. Thermo Fisher Scientific Inc.